FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to polypeptide containing human binding domain capable of binding with epitope of human CD3(epsilon) chain and Callithrix jacchus, Saguinus oedipus or Saimiri sciureus, and additionally containing the second binding domain that binds with cell surface antigen, which is tumor antigen.
EFFECT: obtained polypeptide can be used for the redirection of CD3+ T-cells to tumor cells and for the effective prevention, treatment or weakening of a disease selected from proliferative disease, tumor disease or immunological disorder.
18 cl, 68 dwg, 16 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOVERED ANTIBODY (VERSIONS), A METHOD FOR PRODUCING THE ANTIBODY, AN ISOLATED NUCLEIC ACID, AN EXPRESSION CASSETTE (VERSIONS), A PLASMID (VERSIONS), A HOST CELL, A PHARMACEUTICAL PREPARATION, A KIT, A METHOD OF TREATING A PATIENT, AT RISK OF OR SUFFERING FROM ESCHERICHIA COLI INFECTION, AND A DIAGNOSTIC TECHNIQUE FOR DETERMINING ESCHERICHIA COLI INFECTIONS | 2014 |
|
RU2724530C2 |
| MIC-1 COMPOUNDS AND THEIR USE | 2017 |
|
RU2776529C2 |
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| ANTI-CLDN ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND A METHOD OF ITS DETECTION | 2020 |
|
RU2801315C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
